No Detail Found!

Application of afatinib combined with np regimen in the treatment of stage iv non-small cell lung cancer and its effect on patient survival

Author(s)
Fang Wang Department of Respiratory Medicine, Affiliated Hospital of Hebei University of Engineering,Hebei,China
Zhen Kang Medical College, Hebei University of Engineering,Hebei,China
Ning Wang Department of Respiratory Medicine, Affiliated Hospital of Hebei University of Engineering,Hebei,China
Xian Lin Department of Respiratory Medicine, Affiliated Hospital of Hebei University of Engineering,Hebei,China
Yanli Yi Department of Respiratory Medicine, Affiliated Hospital of Hebei University of Engineering,Hebei,China
Xin Liu Handan Central Hospital,Hebei,China
Yunxiao Tian Handan Central Hospital,Hebei,China
Abstract
To explore the application of afatinib combined with NP regimen in the treatment of stage IV non-small cell lung cancer and its effect on patient survival, the data of 100 patients with stage IV non-small cell lung cancer admitted to our hospital from February 2017 to February 2018 were retrospectively analyzed. They were equally divided into observation group and control group, with 50 in each group. The control group was treated with an NP regimen, and the observation group was treated with afatinib. The disease control rate (DCR) of the observation group was remarkably higher than that of the control group (P<0.05). The observation group witnessed a markedly higher clinical benefit rate relative to the control group (P<0.05). A remarkably longer median treatment failure time of the observation group was observed as compared to the control group (P<0.001). There was no statistical difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). Afatinib combined with NP regimen treatment increases the clinical benefit rate of patients with stage IV non-small cell lung cancer, improves its short-term efficacy, and helps prolong the survival time of patients, with excellent safety profile.
Publication Details
Page(s) 627-633
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: S2, Year: 2022

Request the full text from PASTIC

Keywords
Non-small Cell Lung Cancer, Afatinib, vinorelbine, Cisplatin
References
Aggarwal C,Bubendorf L,Cooper WA,Illei P,Borralho Nunes P,Ong BH,Tsao MS,Yatabe Y,Kerr KM Y .2021 .Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 162 : 42-53.
Medica Associazione .2021 .Ethical principles for medical research involving human subjects]. Assist. Inferm Ric, 20(2) : 104-107.
Cheng S,Pei R,Li J,Li B,Tang L,Yin T,Liu S T .2021 .Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: A cost-effectiveness analysis from US and Chinese perspectives. Ann. Transl. Med, 9(18) : 1481.
Divisi D,De Vico A,Zaccagna G,Irelli A,Aielli F,Cannita K,Martella F K .2021 .NSCLC immunotherapy and related rare toxicities: a monocentric real-life experience. Cancer Med, 4(3) : 115-119.
Evers J,Hendriks LEL,De Jaeger K,Wijsman R,De Ruysscher D,Terhaard C,van der Sangen M,Siesling S,Struikmans H,Aarts MJ H .2021 .Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide populationbased study from the Netherlands. Lung Cancer, 162 : 61-70.
Fang C,Liu T,Liang W,Feng S,Su Z,Tang H,Huang H,Chen Z H .2021 .Clinical pharmacist participation in selecting and dosing targeted drugs for a patient with ALK-positive non-small cell lung cancer: A case report. Ann Transl Med, 9(18) : 1488.
Hill H,Robinson M,Lu L,Slaughter D,Amin A,Mileham K,Patel JN K .2021 .Venous thromboembolism incidence and risk factors in nonsmall cell lung cancer patients receiving first-line systemic therapy. Thromb. Res., 208 : 71-78.
Hockenhull K,Ortega-Franco A,Califano R .2021 .Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: The new kid on the block. Transl Lung Cancer Res, 10(9) : 3850-3854.
Jain P,Khorrami M,Gupta A,Rajiah P,Bera K,Viswanathan VS,Fu P,Dowlati A,Madabhushi A .2021 .Novel non-invasive radiomic signature on ct scans predicts response to platinum-based chemotherapy and is prognostic of overall survival in small cell lung cancer. Front Oncol., 11 : 744724.
Kepp O Kroemer G .2021 .Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade. , 10(1) : 1996686.
Kunimasa K,Okami J,Takenaka S,Honma K,Kukita Y,Nagata S,Kawamura T,Inoue T,Tamiya M,Kuhara H,Nishino K,Tahara H,Kumagai T H .2021 .Conversion surgery for advanced thoracic SMARCA4- deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: A case report. JTO Clin. Res. Rep, 2(11) : 100235.
Li D,Wang Y,Li C,Wang Q,Sun B,Zhang H,He Z,Sun J .2021 .Cancer-speci fi c calcium nanoregulator suppressing the generation and circulation of circulating tumor cell clusters for enhanced antimetastasis combinational chemotherapy. Acta Pharm Sin. B., 11(10) : 3262-3271.
Murat-Ringot A,Souquet PJ,Subtil F,Boutitie F,Preau M,Piriou V .2021 .The effect of foot reflexology on chemotherapy-induced nausea and vomiting in patients with digestive or lung cancer: Randomized controlled trial. JMIR Cancer, 7(4) : e25648.
Okamoto M,Kim YH,Ouchi A,Yamaoka T,Iwamoto N,Iwatsubo S,Matsumura K,Nakamura M,Kin Y,Shiina Y,Funada Y Y .2021 .Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy. Respir. Med. Case Rep, 34 : 101529.
Pan P,Wu F,Xu Z,Ji X,Qi Q,Huang X,Zhao R,Liu M,Jiang P,Li Y,Xu L Y .2021 .Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world. Thorac Cancer, 12(24) : 3416-3425.
Pujol JL,Vansteenkiste J,Paz-Ares Rodriguez L,Gregorc V,Mazieres J,Awad M,Jänne PA,Chisamore M,Hossain AM,Chen Y,Beck JT Y .2021 .Abemaciclib in combination with pembrolizumab for stage IV KRAS-mutant or squamous NSCLC: A phase 1b study. JTO Clin. Res. Rep, 2(11) : 100234.
Sasaki T,Tabata T,Yoshimura N .2021 .For which lung cancer patients is re-administration of immune checkpoint inhibitors effective. J. Rural Med, 16(4) : 256-262.
Saw SPL,Ong BH,Chua KLM,Takano A,Tan DSW .2021 .Revisiting neoadjuvant therapy in non-smallcell lung cancer. Lancet Oncol., 22(11) : e501-e516.
Subramaniyan V,Fuloria S,Gupta G,Kumar DH,Sekar M,Sathasivam KV,Sudhakar K,Alharbi KS,Al-Malki WH,Afzal O,Kazmi I,Al-Abbasi FA,Altamimi ASA,Fuloria NK .2021 .A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer. Chem. Biol. Interact, 351 : 109735.
Terao T,Kumagi T,Hyodo I,Yokota T,Azemoto N,Miyata H,Kuroda T,Ohno Y,Tanaka Y,Shibata N,Imamura Y,Kanemitsu K,Miyake T,Koizumi M,Hiasa Y,Ehime Pancreato-Cholangiology (EPOCH) Study Group Y .2021 .Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Medicine (Baltimore), 100(43) : e27591.
Wang X,Chen D,Wen J,Mao Y,Zhu X,Fan M,Chen Y .2021 .Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: A systematic review and meta-analysis. Ann. Transl. Med, 9(18) : 1430.
Wang ZL,Guo YJ,Zhu YY,Chen L,Wu T,Liu DH,Huang BS,Du HZ .2021 .Active fractions of Camellia nitidissima inhibit non-small cell lung cancer via suppressing epidermal growth factor receptor]. Zhongguo Zhong Yao Za Zhi. , 46(20) : 5362-5371.
Zhao ZR,Yang CP,Chen S,Yu H,Lin YB,Lin YB,Lin YB,Qi H,Jin JT,Lian SS,Wang YZ,You JQ,Zhai WY,Long H WY .2021 .Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology, 10(1) : 1996000.
Zhu Y,Shen L,Zhou Y .2021 .Nano-particulated erlotinib compound system in alleviation of lung cancer. J. Biomed. Nanotechnol., 17(10) : 1984-1992.
0

Citations

0

Downloads

10

Views